Talent & Expertise Open Innovation Technologies International Partnerships

MEET, SHARE AND WORK WITH BIOWIN

OPEN INNOVATION

TALENT & EXPERTISE TECHNOLOGIES

INTERNATIONAL PARTNERSHIPS

1 Photography by Michel Houet 2 Design by Hoet&Hoet Where Science + Business means Partnerships

BioWin is the health competitiveness cluster of Wallonia (Belgium), the region located just South of Brussels. Wallonia, also known as one of the most innovative biotech hubs of Europe, is a unique area of Belgium that is home to more than 116 health companies specializing in health biotechnology and medical technologies. Domains covered by these companies include biopharmacy, cell therapy, radiopharmacy, diagnostics, biotech products, services (CRO, CMO, bioinformatics), medical devices and medical equipment. Major strengths in the ﬁ eld of biotechnology linked to health include: excellence in academic and industrial research; a unique academic and industrial collaborative network; a high concentration of university hospitals (Belgium has the world’s highest proportion of clinical trials per capita with the fastest approval for phase 1 clinical trials in Europe: 2 weeks!); and a broad offering of science parks with incu- bation and innovation centers at a reasonable cost. Making Wallonia’s location of utmost importance.

Created in July 2006, BioWin saw an opportunity nestled among the framework of a major regional socioeconomic program. Focusing on the health sector, the development of this competitiveness cluster aims to provide regional economic growth by creating companies, extending existing ones and by creating jobs in the region. Its initiative was and still is to federate all stakeholders from Wallo- nia who are contributing to innovation and training in the ﬁ eld of biotechnology and health, and who have the ambition to accelerate innovation, by encourag- ing universities and industry (mostly SMEs) to partner with one another.

In these partnerships, industry is given the leading role to ensure that innovative products/services are created for new global markets. To foster these public–private partnerships between universities, companies (both small and large) and research centers, the regional government launches annual calls for projects in which BioWin manages the initial set-up and ensure that they are operational on an international level.

1 Companies- member of BioWin Wallonia has fully-integrated value chains in cutting-edge technological domains such as: Biopharma, Radiopharma, Regenerative Medicine and In Vitro Diagnostics.

Employment split (%) by activity sector (116 innovative companies - without Baxter, GSK Vaccines and UCB).

[21%] MEDICAL EQUIPEMENTS [9%] CONTRACT RESEARCH MEDICAL DEVICES ORGANISATION (CRO) INSTRUMENTS

[9%] BIOTECH PRODUCTS [20%] SUPPORT SERVICES BIOINFORMATICS IT SERVICES [11%] DIAGNOSTICS

[13%] BIOPHARMA [17%] CONTRACT MANUFACTURING ORGANIZATION (CMO)

2 source: M5 Generated an estimated annual turnover of 4.4 billion euros and employing approximately 14,300 people BioWin remains one of the top European competitiveness clusters to date, rapidly acquiring worldwide recognition. The Wallonia region alone is home to world leaders such as GSK Vaccines (...), UCB (CNS and Immunology), Baxter (biopharmaceutical and medical devices), IBA (cancer, radio-diagnostic and therapy), and Eurogentec-Kaneka (biotechnology products and diagnostics). One - third of the workforce of these companies is employed in R & D. This proportion is even higher among the ever- important innovative Small and Medium Enterprises (SME’s) in the region. With over 400 public and private R & D centers, employing more than 11,000 researchers, private expenses in R&D amount to an astonishing 900 million Euros per year.

It is important to note that three academies involving several universities have been created in order to federate the efforts in higher education and academic research: the Académie Universitaire Louvain comprising the Univer- sité Catholique de Louvain (UCL, Louvain) and the Université de Namur; the Académie Universitaire Wallonie–Bruxelles comprising the Université Libre de Bruxelles (ULB, Brussels) and the Université de Mons (UMONS, Mons); and the Académie Universitaire Wallonie–Europe comprising the University of Liège (ULg, Liège).

In addition to the universities, the region is also home to prestigious research institutes including, among several others, the Ludwig Institute of Cancer Research (LICR), the GIGA (Liège), the Institute of Medical Immunology (IMI), or the Christian de Duve Institute of Cellular Pathology (ICP), Winner of the Nobel prize in Medicine.

In 2009, Wallonia and regional stakeholders launched an initiative to support excellence in basic research conducting to potential technology trans- fers in the ﬁ elds of medical, pharmaceutical and veterinary biotechnologies: WELBIO, the institute for Walloon excellence in life sciences and biotechnology. In 2012, BioWin opened a PartnerPort in the Biopark Incubator 2. This service aims to provide the partners who are willing to explore collaborative opportunities in Wallonia with complete ofﬁ ce facilities as well as BioWin support to access health sector key players.

BioWin today = 510 members: 116 companies Turn over: 4,4 billion Euros/year Employment: 14,300 direct jobs Private investments in R&D: 900 million Euros/year 3 university academia

400 research units from 3 universities academia 11,000 researchers Investments (non R&D): 288 million Euros/year 3 The BioWin core activities are centered on:

1 Open Innovation: to foster collaborative R&D projects favorable to scientiﬁ c excellence and innovation leadership in Wallonia.

2 Talents and Expertise: to train, attract, develop and retain a human nucleus of excellence in Wallonia

3 Technology: to help to establish the setting up of collective infrastructures and technological platforms

4 International partnerships: to internationally promote the strengths of Wallonia in the area of health biotechnology and medical technologies

4 1 Open Innovation There are currently 27 Research & Development collaborative projects between industry and academia. The BioWin initiative is to seek out those projects that are not only at the forefront of innovation but that provide a strong sensible business plan with high governing standards. BioWin determines the scope of the calls for projects and helps in the formation of consortia via networking activities. The minimum consortium comprises two academic laboratories from two different universities and two companies, including at least one SME. A project leader from one of the private companies is also chosen. Projects are selected by an international jury that is appointed by BioWin. The BioWin jury (selected according to project criteria) evaluates the scientifi c excellence, as well as the economic potential, of the projects and recommends the most promising ones to the BioWin board. In this aspect, only the best projects, which are able to compete on an international level are fi nally recommended for fi - nancing to the regional government. Approximately eighteen months following the implementation of the project, BioWin and the jury review and evaluate the project. In efforts to maintain good governance practice, these midterm evalu- ations are required by BioWin to determine whether or not the project is on tar- get and moving in the right direction. Through regional funding the project will receive an estimated 3-4 million Euros over the course of 4 years. Since 2006, fi nancial support to the 27 ongoing projects, received from both public and private investors, has reached an outstanding 88,6 million euros.

While the university receives full funding, the large and small companies are re- sponsible for a portion of their investment, emphasizing the importance of the industry’s involvement in the program and it’s development. This ﬁ nancial com- mitment reinforces commercial valorization giving rise to license agreements, creation of spin-offs, joint ventures, etc... In order to maintain the capacities in innovation, cross-fertilization (cross wise techniques) within the region is highly favored. Deﬁ ned by the interaction between biomedical sciences and other technologies, this allows for the development of existing and innovative avenues in the industry. By combining mechanical engineering, logistics, photonics or ICT with biomedical sciences, new sectors such as radiopharmacy, biologistics, biophotonics or e-health are rapidly developing.

- 27 R&D Collaborative projects - Commercial valorisation - Cross wise techniques

5 - Specifi c training courses - In-company trainingships - Multidisciplinary collaborations 2 Talents & Expertise One of BioWin’s initiatives is to provide innovative training programs that are specifi cally tailored to the needs of companies. BioWin prepares for the future with open innovation at a regional level by helping businesses needing highly- skilled staff fi nd the right training programs and expertise. Several sessions each year are organized on subjects as varied as quality control, clinical studies, intellectual property and entrepreneurship. This project aims to update and/or upgrade the know-how of employees. However, these sessions are also open to students, university professors and job seekers wishing to broaden their knowledge in a particular sector. BioWin shares this initiative with other clusters in the Wallonia region.

Another initiative builds bridges between universities and industry via in- company traineeships for students as well as through continued education programs for professionals. These programs are intended to encourage students and professionals to expand their knowledge base and stay up-to-date on new developments in a particular area of expertise.

By providing the necessary education and training, BioWin can deliver the support and expertise required in order for the business to remain competitive on an international level. In addition, there is currently a training framework program that focus on key competencies in order to boost multidisciplinary collaborations: the BioPharE project. The objective of this project is to ensure the strategic piloting of the training programs offered and the development of competencies proposed by different operators meet the demand of the leaders in the Biotech health sector of Wallonia. There are currently 14 ongoing projects focusing around the development of “Talents and Expertise” in BioWin’s area. 3 Technology BioWin encourages and supports any idea for a collaborative project designed to create an innovative technological platform and/or fulﬁ ll a need for a critical infrastructure for the development of the biomedical sector in Wallonia. The priority - Technological of these platforms is to facilitate or accelerate the process of bringing innovative Plateforms products, processes or services to market. - Cell Therapy In general, an innovation platform is a physical or virtual sharedand open infrastructure that offers skills and services. It is set up on the initiative of businesses, - Biobanking approved by clusters and recognised by the international jury working closely with the authorities concerned. - Protontherapy

Its creation is based on a shared range of technological skills or services aimed at members of the cluster. To do this, the platforms draw in everyone involved from the clusters in question: the SMEs (as a priority), large corporations, university laboratories and research centres. That having been said, without exception the platforms are not designed to take on basic research projects. Only projects involving innovative or emerging technologies are considered.

Pooling skills helps to generate economies of scale and encourages synergies between industrial and academic partners, with the ultimate aim of creating shared strategic added value for Wallonia

6 4 International Partnerships Within the context of its international activities, BioWin is keen to promote the scientiﬁ c and industrial expertise of its members beyond Wallonia’s borders. It goes without saying that this goal is key to the economic success of the development of innovation ; the products and services that are inherent to the ﬁ eld of health are essentially targeting the global market. With this in mind, the cluster is regularly involved in activities that complement those implemented by the AWEX (Wallonia Foreign Trade and Investment Agency) to facilitate interaction between those involved in health innovation based in Wallonia, as well as those based in other parts of Europe and the world. In that spirit, BioWin also hired 3 permanent representatives (in Europe, in Boston and in Shanghai) whose main missions are to identify and validate potential technological partnerships for the members of the cluster.

Promoting BioWin’s members internationally also involves greater recognition of the talent for innovation boasted by the region itself. BioWin has therefore also given itself the task of establishing Wallonia as an undisputed key player in the biotechnology, health and medical technology sectors.

Nurturing and promoting Wallonia’s scientifi c and industrial innovation on an international scale, essentially supported by the regional authorities, is also designed to consolidate Wallonia’s appeal to fi nancial and industrial investors, potential partners active in the fi eld of R&D and human resources based abroad.

As part of its internationalisation strategy, BioWin runs communication cam- paigns, organises networking events with other health clusters, takes part in European projects, enters into partnerships in Europe and further aﬁ eld, and establishes permanent representatives in regions showing great development potential in terms of business and innovation.

- EU funded programs - European Diagnostic Clusters Alliance - Shanghai - SBIA, JUKE Biotech Park -Shanghai BioClouds - Massachusetts Life Sciences Center (MLSC) - MassBio Boston

7 BioWin Be Part of It!

Supportive professional environment:

The innovation partners can rely on BioWin to boost their innovation and as on many other supportive organizations and networks:

AT THE REGIONAL LEVEL (WALLONIA): > WELBIO, for the support of basic research in health domains; > Agence de Stimulation Technologique (AST) or Stimulation technology agency: the mission of this structure is to collect and coordinate the divers operators who are current participants in scientiﬁ c intermediation and technology. > Technology Development Department (DG06): Wallonia has designed a series of incentives to boost innovation in Wallonia. R&D incentives include: grants for basic industrial research, refundable advances for applied research (up to 75 % of the R&D cost), speciﬁ c assistance (such as technical and economic studies, human resources, technology transfer support). > The LIEU Network(Liaison Entreprises-Universités) regroups cells and inter- faces of valorization among the top universities and schools in the Wallonia- Brussels region, Your door to expertise among the Universities and higher education school systems. > Essenscia Wallonia, represents and defends the interests of chemicals and life sciences sectors in matters for which Wallonia and the French-speaking Community of Belgium are competent. > Walloon Export and Investment Agency (AWEX): the Foreign investment di- vision of the AWEX has its own Life Sciences Expert dedicated to help you through every steps of your investment project.

8 AT THE FEDERAL LEVEL Bio.be (Essenscia), the Belgian federation of biotechnologies UNAMEC, the trade association for medical devices and diagnostics businesses

AT EUROPEAN LEVEL EuropaBio, the European Association for Bioindustries, the voice for the biotech industry at the EU level European Biopharmaceutical Enterprises (EBE), the European trade association that represents biopharmaceutical companies of all sizes operating in Europe

Competitive tax environment The combination of several focused tax measures makes Belgium one of the most attractive investment locations for research, development and production in the European Union. These measures include: > The lowest European tax rate on revenue from royalty income (de facto 6.8%) > A 75% payroll tax deduction for company researchers (PhD, engineers and Master degrees) > R&D investment deductions > National interest deduction on corporate tax when making investments based on equity

Wallonia : Strategic location in Europe - First in logistics > Strategically and centrally positioned at the political heart of Europe: presence of many international organizations e.g. European Institutions, and major corporate headquarters > Easy access to a potential market of 500 million people thanks to a highly effective logistics network (Wallonia N°1 in EU for Logistics (Cushman and Wakeﬁ eld 2009)) > A ﬁ rst-class logistical and business infrastructure: excellent transport facilities by road, rail, water and air, top rate telecommunications network

An attractive and comfortable region to live in. > Competitively low real estate costs compared to other European countries > A highly developed transport network (speed train, airports, highways, ..) > A multicultural and multilingual population (English widely spoken) > Many high-level international schools– > High standard/ quality of living

9 BioWin - Contact persons

GENERAL MANAGEMENT BIOWIN REPRESENTATIVES TRAINING & COMPETENCES (OUTSIDE WALLONIA) TECHNOLOGICAL PLATFORMS France Fannes EUROPE [email protected] Laurence Timmermans [email protected] SCIENTIFIC DEPARTMENT Sylvie Ponchaut (PhD) ASIA [email protected] Laurent Le Guyader (Shanghai) [email protected] COMMUNICATION INTERNATIONAL RELATIONS USA Frédéric Druck Horacio Caperan (Boston/Massachusetts) [email protected] [email protected]

BioWin is member of

BioWin is co-founder of The Europe Diagnostic Clusters Alliance (EDCA)

10 BioWin members

COMPANIES 4 CLINICS • ADVANCED TECHNOLOGY CORPORATION (ATC) • AEPODIA • AIR CONSULT ENGINEERING • AKKA BENELUX • ALLIANSES • AMD - ADVANCED MEDICAL DIAGNOSTIC • AMHYSPIN CECOTEPE • ANALIS R&D DIAG • ARAPONICS • ARLENDA • ARTIALIS • ASEPTIC TECHNOLOGIES • B&C GROUP • BAXTER • BELDEM - PURATOS GROUP • BELGIAN VOLITION RX • BENECHIM • BIION • BIO PHARMA LOGISTICCS (BPL) • BIOLOGISTICS CONSULTING • BIO-PLUS SERVICES • BIOTECH CONSULT • BIOTECH TOOLS FACTORY • BONE THERAPEUTICS • CARDIATIS • CARDIO3 BIOSCIENCES • CENEXI LABORATOIRES THISSEN • CMI (CLEANROOM MANAGEMENT INTERNATIONAL) • CMMI • CORIS BIOCONCEPT • CRNA • CROPHA • DELPHI GENETICS • DIAGAM • DIASOURCE IMMUNOASSAYS EUROPE • DNA VISION • DNALYTICS • D-TEK • ECKERT & ZIEGLER BEBIG • EGEMIN AUTOMATION • ENDO TOOLS THERAPEUTICS • EONIX • EPPENDORF ARRAY TECHNOLOGIES (EAT) • E-PROTEIN • ERC • EUROGENTEC-KANEKA • EUROSCREEN • FENWAL EUROPE • GALEPHAR • GLAXOSMITHKLINE VACCINES • H&O EQUIPMENTS • HENOGEN - NOVASEP • HUMAN WAVES • I.P.B.M. - INTERNATIONAL PROJECT & BUSINESS MANAGEMENT • IBA • IDDI • IDS • IMCYSE • INSTITUT DE PATHOLOGIE GÉNÉTIQUE (IPG) • IPRATECH • IRE • IRE-ELIT • ISTAR MEDICAL • IT4IP • ITEOS THERAPEUTICS • IXEMEL • KELLY SCIENTIFIC RESOURCES • KEYRUS BIOPHARMA • KITOZYME • LABO BELGE DE THERMOMÉTRIE (LBT) • LABO LIFE BELGIUM • LONZA • M5 • MASTHERCELL • MDXHEALTH • MEDEX LONCIN • MEDI-LINE • MITHRA PHARMACEUTICALS • NEUROTECH • N-SIDE • NYXOAH • ONCODNA • OVOGENICS • PALANTIRIS • PECHER CONSULTANTS • PFIZER GLOBAL MANUFACTURING • PHARMA INSIGHT • PHARMED • PLUS ONE • PM GROUP BELGIUM • PROBIOX • PROGENOSIS • PROGENUS • PROMATIC W - ACTEMIUM • PROMETHERA BIOSCIENCES • PRONOVEM • QUALITY ASSISTANCE • RLM CONSULTING • ROMMEL CONSULTING PARTNERS • SGS LIFE SCIENCE SERVICES • SHANT LABORATORIES • SIFEC • STERIGENICS • STRATEX CONSULTING • STRATICELL • SYNOLYNE • TARGETOME • TEMPLAB • TILMAN • TRASIS • UCB • UTERON PHARMA • VALIBIO • VEGOB CONSULT • VITALTRONICS • WHITE WAVE • WOW TECHNOLOGY • XIBIOS • X-RIS • ZENTECH

UNIVERSITIES ACADÉMIE UNIVERSITAIRE LOUVAIN UNIVERSITÉ CATHOLIQUE DE LOUVAIN (UCL, LOUVAIN) AND UNIVERSITY OF NAMUR

ACADÉMIE UNIVERSITAIRE WALLONIE–BRUXELLES UNIVERSITÉ LIBRE DE BRUXELLES (ULB, BRUSSELS) AND THE UNIVERSITÉ DE MONS (UMONS, MONS)

ACADÉMIE UNIVERSITAIRE WALLONIE–EUROPE UNIVERSITY OF LIÈGE (ULG, LIÈGE)

+ 400 RESEARCH UNITS

NON-UNIVERSITY RESEARCH CENTERS CENAERO • CENTEXBEL • CER GROUPE • CETIC • IMMUNEHEALTH • MULTITEL • SIRRIS WALLONIE

32 HIGHER EDUCATION SCHOOLS

COMPETENCE CENTERS & PARTNERS BIOPARK BRUSSELS SOUTH • CEFOCHIM • CULTURE IN VIVO • FOREM - GIGA • HEC BUSINESS SCHOOL - ULG ICHECH PME • LOUVAIN SCHOOL OF MANAGEMENT • PHARMED • SOLVAY BRUSSELS SCHOOL (SBS) • VIVIDLINKS.EU OTHER STAKEHOLDERS AWEX • CIDE SOCRAN • ESSENSCIA • CAPITAL CROISSANCE - GROUPE INVESTSUD • TECHNOWAL-SRIW VESALIUS BIOCAPITAL • WALLONIA BIOTECH COACHING • BIOPARK INCUBATOR 1 & 2

01/04/2013 / Detailed BioWin members list (including activities and expertise) on www.biowin.org Up-to-date insights (investments, innovations,partnerships) on http://win-health.org, the Health blog of Wallonia. 11 BIOWIN, WHERE SCIENCE

MEETS BUSINESS • 116 BIOTECH/PHARMA COMPANIES 14.300 DIRECT JOBS • SCIENTIFIC EXCELLENCE IN RESEARCH UNITS FROM 3 MAIN UNIVERSITY SYSTEMS • 7 MAJOR UNIVERSITY HOSPITALS • WALLONIA IS RECOGNIZED AS A EUROPEAN LEADER IN CLINICAL RESEARCH • ON TOP OF ITS INNOVATION CAPACITIES IN HEALTH, THE REGION BENEFITS FROM A UNIQUE LOGISTIC LOCATION, FAVORABLE OPEN INNOVATION TAX ENVIRONMENT AND R&D INCENTIVES

TALENTS & EXPERTISES TECHNOLOGIES

INTERNATIONAL PARTNERSHIPS

FOR UP-TO-DATE INSIGHT FROM BIOWIN MEMBERS ABOUT THEIR INNOVATIONS, INVESTMENTS AND PARTNERSHIPS, VISIT WWW.WIN-HEALTH.ORG, THE HEALTH BLOG OF WALLONIA WWW.BIOWIN.ORG

12 BIOWIN, WHERE SCIENCE

TALENTS & EXPERTISES TECHNOLOGIES

INTERNATIONAL PARTNERSHIPS

FOR UP-TO-DATE INSIGHT FROM BIOWIN MEMBERS ABOUT THEIR INNOVATIONS, INVESTMENTS AND PARTNERSHIPS, VISIT WWW.WIN-HEALTH.ORG, THE HEALTH BLOG OF WALLONIA WWW.BIOWIN.ORG

WITH THE SUPPORT OF 14 Wallonia